Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NB001 in Acute Treatment of Migraine
NCT07577050Phase 2Not yet recruiting
- Sponsor
- Chinese PLA General Hospital
- Start
- Apr 2026
- Primary completion
- Sep 2026
- Modality
- Nanoparticles, Small Molecules
01
Overview
A Phase 2 trial of cetylpyridinium chloride in migraine, sponsored by Chinese PLA General Hospital. Planned start Apr 2026; status: not yet recruiting.
02
Drugs
cetylpyridinium chloride
03
Conditions
migraine
Beyond the preview
Go deeper on NCT07577050.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07577050.